Yidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops

Reuters

09/23

<a href="https://laohu8.com/S/YIDUF">Yidu Tech Inc.</a> Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops

Yidu Tech Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569765343"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569765343\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569765343?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 12:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569765343","market":"us","top_or_hot":-1,"title":"Yidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/YIDUF\">Yidu Tech Inc.</a> Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/02158\">Yidu Tech</a> Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-23 12:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/YIDUF\">Yidu Tech Inc.</a> Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/02158\">Yidu Tech</a> Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300143","symbol_name":"盈康生命","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL8MRQLf:1","article_id":"2569765343","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569765343","pubTimestamp":1758600357,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Yidu Tech Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor  Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300143":"盈康生命","02158":"医渡科技","BK1189":"医疗保健技术","BK1617":"AI医疗","BK1518":"SaaS概念","BK0236":"卫生"},"translate_title":"医渡科技宣布成功中标SMR001滴眼液III期临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300143":0.9,"02158":0.9},"content_text":"Yidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops\n    \n\nYidu Tech Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}